| Inotersen treatment for patients with hereditary transthyretin amyloidosis MD Benson, M Waddington-Cruz, JL Berk, M Polydefkis, PJ Dyck, ... New England Journal of Medicine 379 (1), 22-31, 2018 | 1210 | 2018 |
| Regional variation of Guillain-Barré syndrome AY Doets, C Verboon, B Van Den Berg, T Harbo, DR Cornblath, ... Brain 141 (10), 2866-2877, 2018 | 294 | 2018 |
| Long‐term safety and efficacy of eculizumab in generalized myasthenia gravis S Muppidi, K Utsugisawa, M Benatar, H Murai, RJ Barohn, I Illa, S Jacob, ... Muscle & nerve 60 (1), 14-24, 2019 | 183 | 2019 |
| International Guillain‐Barré Syndrome Outcome Study: protocol of a prospective observational cohort study on clinical and biological predictors of disease course and outcome in … BC Jacobs, B van den Berg, C Verboon, G Chavada, DR Cornblath, ... Journal of the Peripheral Nervous System 22 (2), 68-76, 2017 | 117 | 2017 |
| Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study D Adams, M Polydefkis, A González-Duarte, J Wixner, AV Kristen, ... The Lancet Neurology 20 (1), 49-59, 2021 | 115 | 2021 |
| Long-term safety and efficacy of tafamidis for the treatment of hereditary transthyretin amyloid polyneuropathy: results up to 6 years FA Barroso, DP Judge, B Ebede, H Li, M Stewart, L Amass, MB Sultan Amyloid 24 (3), 194-204, 2017 | 109 | 2017 |
| Current treatment practice of Guillain-Barré syndrome C Verboon, AY Doets, G Galassi, A Davidson, W Waheed, Y Péréon, ... Neurology 93 (1), e59-e76, 2019 | 82 | 2019 |
| Oligonucleotide Drugs for Transthyretin Amyloidosis. JL Berk, FA Barroso, T Coelho The New England journal of medicine 379 (21), 2085, 2018 | 67 | 2018 |
| Early data on long‐term efficacy and safety of inotersen in patients with hereditary transthyretin amyloidosis: a 2‐year update from the open‐label extension of the NEURO‐TTR trial TH Brannagan, AK Wang, T Coelho, M Waddington Cruz, MJ Polydefkis, ... European journal of neurology 27 (8), 1374-1381, 2020 | 58 | 2020 |
| Second IVIg course in Guillain-Barré syndrome with poor prognosis: the non-randomised ISID study C Verboon, B Van Den Berg, DR Cornblath, E Venema, KC Gorson, ... Journal of Neurology, Neurosurgery & Psychiatry 91 (2), 113-121, 2020 | 52 | 2020 |
| Differences between acute‐onset chronic inflammatory demyelinating polyneuropathy and acute inflammatory demyelinating polyneuropathy in adult patients L Alessandro, JM Pastor Rueda, M Wilken, L Querol, M Marrodán, ... Journal of the Peripheral Nervous System 23 (3), 154-158, 2018 | 34 | 2018 |
| Management of asymptomatic gene carriers of transthyretin familial amyloid polyneuropathy HHJ Schmidt, F Barroso, A González‐Duarte, I Conceição, L Obici, ... Muscle & nerve 54 (3), 353-360, 2016 | 34 | 2016 |
| Predicting Outcome in Guillain-Barré Syndrome: International Validation of the Modified Erasmus GBS Outcome Score AY Doets, HF Lingsma, C Walgaard, B Islam, N Papri, A Davidson, ... Neurology, 2021 | 31 | 2021 |
| Hereditary transthyretin amyloidosis: baseline characteristics of patients in the NEURO-TTR trial M Waddington-Cruz, EJ Ackermann, M Polydefkis, SB Heitner, PJ Dyck, ... Amyloid 25 (3), 180-188, 2018 | 30 | 2018 |
| Blood pressure and orthostatic hypotension as measures of autonomic dysfunction in patients from the transthyretin amyloidosis outcomes survey (THAOS) A González-Duarte, F Barroso, R Mundayat, B Shapiro Autonomic Neuroscience 222, 102590, 2019 | 29 | 2019 |
| HNRNPDL-related muscular dystrophy: expanding the clinical, morphological and MRI phenotypes A Berardo, X Lornage, M Johari, T Evangelista, C Cejas, F Barroso, ... Journal of neurology 266 (10), 2524-2534, 2019 | 24 | 2019 |
| Consistent improvement with eculizumab across muscle groups in myasthenia gravis R Mantegazza, FL O'Brien, M Yountz, JF Howard Jr, REGAIN study group, ... Annals of clinical and translational neurology 7 (8), 1327-1339, 2020 | 20 | 2020 |
| Long-term efficacy and safety of eculizumab in Japanese patients with generalized myasthenia gravis: A subgroup analysis of the REGAIN open-label extension study H Murai, A Uzawa, Y Suzuki, T Imai, H Shiraishi, H Suzuki, M Okumura, ... Journal of the neurological sciences 407, 116419, 2019 | 20 | 2019 |
| International validation of the Erasmus GBS Respiratory Insufficiency Score AY Doets, C Walgaard, HF Lingsma, B Islam, N Papri, Y Yamagishi, ... Annals of Neurology, 2022 | 16 | 2022 |
| Eculizumab in refractory generalized myasthenia gravis previously treated with rituximab: subgroup analysis of REGAIN and its extension study ZA Siddiqi, RJ Nowak, T Mozaffar, F O'Brien, M Yountz, F Patti, ... Muscle & nerve 64 (6), 662-669, 2021 | 12 | 2021 |
